1k citations
- Roche (Switzerland)CH5 papers
- Novartis (Switzerland)CH4 papers
- Science Wares (United States)US4 papers
- University of TorontoCA4 papers
- Bayer (Germany)DE3 papers
- Google (United States)US3 papers
- Imperial College LondonGB3 papers
- Pacific Northwest National LaboratoryUS3 papers
- AstraZeneca (United Kingdom)GB2 papers
- Boehringer Ingelheim (China)CN2 papers
- Boehringer Ingelheim (Egypt)EG2 papers
- Bristol-Myers Squibb (Germany)DE2 papers
6 papers · 1 filter
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- estimation of adverse event risks
Regina Stegherr, Claudia Schmoor, Jan Beyersmann +12
The SAVVY project aims to improve the analyses of adverse event (AE) data in clinical trials through the use of survival techniques appropriately dealing with varying follow-up tim…
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- comparison of adverse event risks in randomized controlled trials
Kaspar Rufibach, Regina Stegherr, Claudia Schmoor +12
Analyses of adverse events (AEs) are an important aspect of the evaluation of experimental therapies. The SAVVY (Survival analysis for AdVerse events with Varying follow-up times)…
Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans
Michael Roberts, Derek Driggs, Matthew Thorpe +13
Machine learning methods offer great promise for fast and accurate detection and prognostication of COVID-19 from standard-of-care chest radiographs (CXR) and computed tomography (…
Heterogeneity Learning for SIRS model: an Application to the COVID-19
Guanyu Hu, Junxian Geng
We propose a Bayesian Heterogeneity Learning approach for Susceptible-Infected-Removal-Susceptible (SIRS) model that allows underlying clustering patterns for transmission rate, re…
Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -- Application of the Estimand Framework
Evgeny Degtyarev, Kaspar Rufibach, Yue Shentu +10
COVID-19 outbreak has rapidly evolved into a global pandemic. The impact of COVID-19 on patient journeys in oncology represents a new risk to interpretation of trial results and it…
A mechanistic framework for a priori pharmacokinetic predictions of orally inhaled drugs
Niklas Hartung, Jens Borghardt
The fate of orally inhaled drugs is determined by pulmonary pharmacokinetic (PK) processes such as particle deposition, pulmonary drug dissolution, and mucociliary clearance. Altho…